Medicines Co (MDCO) 39.81 $MDCO
The Medicines Co. to Get BARDA Funding for Infection Drugs
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
CBM: 46.12 (-0.48), MDCO: 39.81 (-0.64), ANIP: 65.36 (-1.28), ANIK: 45.82 (-1.10)
Blog Coverage Medicines Company in a Strategic Partnership with BARDA to Develop a New Range of Antibiotics
ACCESSWIRE - Thu Sep 22, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 22, 2016 / Active Wall St. blog coverage looks at the headline from The Medicines Company (NASDAQ: MDCO) as the company announced on September 21, 2016, that the U.S. Department of Health and Human Services' (HSS) Office of the Assistant Secretary for Preparedness and Response (ASPR) had selected it for a strategic partnership to develop a new range of innovative drugs that would be effective in handling the increasing threat of bacterial infections that are multi-drug resistant. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
MDCO: 39.81 (-0.64)
The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA
BusinessWire - Wed Sep 21, 6:30AM CDT
----First portfolio-based strategic partnership between the Biomedical Advanced Research and Development Authority (BARDA) and a U.S. headquartered company--
MDCO: 39.81 (-0.64)
CORRECTING and REPLACING The Medicines Company Provides Update on Dyslipidemia Programs
BusinessWire - Wed Aug 31, 2:25PM CDT
The third paragraph of release dated August 30, 2016, should read: The Company has completed enrollment of the planned 120 patients and expects that results from the MILANO-PILOT study will be presented by its principal investigator, Dr. Stephen J. Nicholls, MBBS, Ph.D., FRACP South Australian Health and Medical Research Institute, Adelaide, Australia, in the Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions 2016 on November 15, 2016 in New Orleans (instead of: xxx its principal investigator, Dr. Steven Nissen of the Cleveland Clinic, in the Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions 2016 on November 15, 2016 in New Orleans).
MDCO: 39.81 (-0.64)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 39.81 (-0.64), AMGN: 173.53 (-1.27), SNY: 38.04 (-0.31), REGN: 404.12 (-6.27)
The Medicines Company Provides Update on Dyslipidemia Programs
BusinessWire - Tue Aug 30, 3:30PM CDT
The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 39.81 (-0.64)
Watch for Medicines Co to Potentially Pullback After Gaining 1.93% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 2:57PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $39.05 to a high of $40.74. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $40.55 on volume of 625,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 71.10 (-5.21), MDCO: 39.81 (-0.64), CORT: 6.50 (+0.01), PCRX: 35.00 (-1.86)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 15.51 (-0.21), MDCO: 39.81 (-0.64), CBYL: 0.48 (-0.02), PCRX: 35.00 (-1.86)
After Yesterday's Rally of 1.11% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 4:26PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $37.74 to a high of $39.02. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $38.37 on volume of 285,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 71.10 (-5.21), MDCO: 39.81 (-0.64), CORT: 6.50 (+0.01), PCRX: 35.00 (-1.86)
Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 71.10 (-5.21), IRWD: 15.51 (-0.21), MDCO: 39.81 (-0.64), EXEL: 15.31 (+0.42)
The Medicines Company Prices $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 9:14PM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023. The notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be senior unsecured obligations of the Company and will mature on July 15, 2023, unless earlier converted, redeemed or repurchased in accordance with their terms. The notes will bear interest at a rate of 2.75% per year, payable semi-annually. The notes will be convertible prior to April 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The conversion rate for the notes will initially be 20.4198 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $48.97 per share of common stock. The initial conversion price of the notes represents a premium of approximately 32.5% to the $36.96 per share last reported sale price of the Company's common stock on June 6, 2016. The Company has granted to the initial purchasers the option to purchase up to an additional $52.5 million in aggregate principal amount of the notes. The sale of the notes is expected to close on or about June 10, 2016, subject to customary closing conditions.
MDCO: 39.81 (-0.64)
Medicines Co Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Mon Jun 06, 4:25PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $36.10 to a high of $38.49. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $38.33 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 39.81 (-0.64), DPLO: 29.11 (-0.10), CTLT: 26.21 (-0.49), CBYL: 0.48 (-0.02)
The Medicines Company Announces Intention to Offer $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 5:57AM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company" today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be convertible, upon certain conditions, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and the initial purchasers of the notes. The Company also expects to grant to the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of the notes.
MDCO: 39.81 (-0.64)
The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si
BusinessWire - Thu Jun 02, 6:00AM CDT
--Randomized 501 patients with high cardiovascular risk and high LDL-C ("bad cholesterol" despite current treatment
MDCO: 39.81 (-0.64)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 39.81 (-0.64), ANIP: 65.36 (-1.28), RTRX: 22.36 (-0.21), ACOR: 22.99 (-4.29)
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of CARBAVANCE(R) (meropenem-vaborbactam) for Treatment of Complicated Urinary Tract Infections (cUTI)
BusinessWire - Thu May 26, 3:31PM CDT
The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE(R) (meropenem-vaborbactam), an investigational agent being developed for the treatment of complicated urinary tract infections (cUTI). TANGO 1 was initiated in the fourth quarter of 2014 under a cost-share agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of CARBAVANCE. Top-line data are expected in the second half of 2016.
MDCO: 39.81 (-0.64)
The Medicines Company to Present at Two Upcoming Investor Conferences
BusinessWire - Wed May 25, 4:54PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences:
MDCO: 39.81 (-0.64)
The Medicines Co. to Get BARDA Funding for Infection Drugs
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
CBM: 46.12 (-0.48), MDCO: 39.81 (-0.64), ANIP: 65.36 (-1.28), ANIK: 45.82 (-1.10)
Blog Coverage Medicines Company in a Strategic Partnership with BARDA to Develop a New Range of Antibiotics
ACCESSWIRE - Thu Sep 22, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 22, 2016 / Active Wall St. blog coverage looks at the headline from The Medicines Company (NASDAQ: MDCO) as the company announced on September 21, 2016, that the U.S. Department of Health and Human Services' (HSS) Office of the Assistant Secretary for Preparedness and Response (ASPR) had selected it for a strategic partnership to develop a new range of innovative drugs that would be effective in handling the increasing threat of bacterial infections that are multi-drug resistant. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
MDCO: 39.81 (-0.64)
The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA
BusinessWire - Wed Sep 21, 6:30AM CDT
----First portfolio-based strategic partnership between the Biomedical Advanced Research and Development Authority (BARDA) and a U.S. headquartered company--
MDCO: 39.81 (-0.64)
CORRECTING and REPLACING The Medicines Company Provides Update on Dyslipidemia Programs
BusinessWire - Wed Aug 31, 2:25PM CDT
The third paragraph of release dated August 30, 2016, should read: The Company has completed enrollment of the planned 120 patients and expects that results from the MILANO-PILOT study will be presented by its principal investigator, Dr. Stephen J. Nicholls, MBBS, Ph.D., FRACP South Australian Health and Medical Research Institute, Adelaide, Australia, in the Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions 2016 on November 15, 2016 in New Orleans (instead of: xxx its principal investigator, Dr. Steven Nissen of the Cleveland Clinic, in the Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions 2016 on November 15, 2016 in New Orleans).
MDCO: 39.81 (-0.64)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 39.81 (-0.64), AMGN: 173.53 (-1.27), SNY: 38.04 (-0.31), REGN: 404.12 (-6.27)
The Medicines Company Provides Update on Dyslipidemia Programs
BusinessWire - Tue Aug 30, 3:30PM CDT
The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 39.81 (-0.64)
Watch for Medicines Co to Potentially Pullback After Gaining 1.93% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 2:57PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $39.05 to a high of $40.74. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $40.55 on volume of 625,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 71.10 (-5.21), MDCO: 39.81 (-0.64), CORT: 6.50 (+0.01), PCRX: 35.00 (-1.86)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 15.51 (-0.21), MDCO: 39.81 (-0.64), CBYL: 0.48 (-0.02), PCRX: 35.00 (-1.86)
After Yesterday's Rally of 1.11% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 4:26PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $37.74 to a high of $39.02. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $38.37 on volume of 285,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 71.10 (-5.21), MDCO: 39.81 (-0.64), CORT: 6.50 (+0.01), PCRX: 35.00 (-1.86)
Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 71.10 (-5.21), IRWD: 15.51 (-0.21), MDCO: 39.81 (-0.64), EXEL: 15.31 (+0.42)
The Medicines Company Prices $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 9:14PM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023. The notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be senior unsecured obligations of the Company and will mature on July 15, 2023, unless earlier converted, redeemed or repurchased in accordance with their terms. The notes will bear interest at a rate of 2.75% per year, payable semi-annually. The notes will be convertible prior to April 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The conversion rate for the notes will initially be 20.4198 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $48.97 per share of common stock. The initial conversion price of the notes represents a premium of approximately 32.5% to the $36.96 per share last reported sale price of the Company's common stock on June 6, 2016. The Company has granted to the initial purchasers the option to purchase up to an additional $52.5 million in aggregate principal amount of the notes. The sale of the notes is expected to close on or about June 10, 2016, subject to customary closing conditions. MDCO: 39.81 (-0.64)
Medicines Co Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Mon Jun 06, 4:25PM CDT
Medicines Co (NASDAQ:MDCO) traded in a range yesterday that spanned from a low of $36.10 to a high of $38.49. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $38.33 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDCO: 39.81 (-0.64)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 39.81 (-0.64), DPLO: 29.11 (-0.10), CTLT: 26.21 (-0.49), CBYL: 0.48 (-0.02)
The Medicines Company Announces Intention to Offer $350 Million of Convertible Notes
BusinessWire - Mon Jun 06, 5:57AM CDT
The Medicines Company (NASDAQ:MDCO) (the "Company"
today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be convertible, upon certain conditions, into cash, shares of the Company's common stock or a combination thereof, at the Company's option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and the initial purchasers of the notes. The Company also expects to grant to the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of the notes. MDCO: 39.81 (-0.64)
The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si
BusinessWire - Thu Jun 02, 6:00AM CDT
--Randomized 501 patients with high cardiovascular risk and high LDL-C ("bad cholesterol"
despite current treatment MDCO: 39.81 (-0.64)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 39.81 (-0.64), ANIP: 65.36 (-1.28), RTRX: 22.36 (-0.21), ACOR: 22.99 (-4.29)
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of CARBAVANCE(R) (meropenem-vaborbactam) for Treatment of Complicated Urinary Tract Infections (cUTI)
BusinessWire - Thu May 26, 3:31PM CDT
The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE(R) (meropenem-vaborbactam), an investigational agent being developed for the treatment of complicated urinary tract infections (cUTI). TANGO 1 was initiated in the fourth quarter of 2014 under a cost-share agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of CARBAVANCE. Top-line data are expected in the second half of 2016.
MDCO: 39.81 (-0.64)
The Medicines Company to Present at Two Upcoming Investor Conferences
BusinessWire - Wed May 25, 4:54PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences:
MDCO: 39.81 (-0.64)
